HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma (Q2906475): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Added qualifier: readability score (P590521): 0.000011549073841409742) |
||||||
Property / summary: None (English) / qualifier | |||||||
readability score: 0.000011549073841409742
|
Latest revision as of 09:43, 7 March 2024
Project Q2906475 in Portugal
Language | Label | Description | Also known as |
---|---|---|---|
English | HyTherCaP.: Hydralazine: A new therapeutic approach in Castration Resistant Prostate Carcinoma |
Project Q2906475 in Portugal |
Statements
203,999.02 Euro
0 references
239,998.85 Euro
0 references
85.0 percent
0 references
1 January 2018
0 references
30 June 2021
0 references
INSTITUTO PORTUGUÊS DE ONCOLOGIA DO PORTO FRANCISCO GENTIL - E.P.E.
0 references
14 November 2023
0 references
Identifiers
POCI-01-0145-FEDER-029030
0 references